Wu Y-L et al. -The efficacy and safety of dacomitinib was compared with gefitinib in the first-line treatment of patients with advanced EGFR-mutation-positive NSCLC. It was shown that dacomitinib significantly improved PFS over gefitinib.

Methods

• Adults ≥18 years of age (or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) were enrolled from 71 academic medical centres and university hospitals in 7 countries.
• Patients received oral dacomitinib (45 mg/day in 28-day cycles) or oral gefitinib (250 mg/day in 28-day cycles) until disease progression.

Results

• 452 patients were enrolled.
• The median duration of follow-up for PFS was 22.1 months.
• The median PFS was 14.7 months in the dacomitinib group and 9.2 months in the gefitinib group (HR = 0.59).